Connect Biopharma Reports Promising Rademikibart Trial Outcomes for Atopic Dermatitis

Connect Biopharma Holdings Limited (NASDAQ:CNTB, a clinical-stage biopharmaceutical company specializing in the development of novel immune modulators, has recently shared optimistic long-term results from the China pivotal trial of Rademikibart, its leading candidate for the treatment of moderate-to-severe atopic dermatitis. The positive data emerged as a significant milestone for the company, demonstrating sustained efficacy over a prolonged period in a considerable segment of the patient population under study.

Long-term Efficacy Demonstrated in Atopic Dermatitis Trial

From the comprehensive evaluation conducted over 52 weeks, around 90% of the participants who received a quarterly dose of Rademikibart were able to maintain both an Investigator's Global Assessment (IGA) score of 0/1 and a 75% improvement in the Eczema Area and Severity Index (EASI-75). This finding not only underscores the durability of Rademikibart's therapeutic effect but also positions it as a potential game-changing therapy for individuals grappling with the challenges of atopic dermatitis.

Significance of the Study Findings

The robust outcomes that patients on the Q4W dosing regimen exhibited through Week 52 point to the stable and persistent efficacy of Rademikibart in ameliorating the symptoms associated with moderate-to-severe atopic dermatitis. The success of the trial further solidifies the scientific underpinnings of Connect Biopharma's commitment to addressing the unmet medical needs in the realm of autoimmune diseases and inflammatory conditions. Connect Biopharma's advancements also hold promise for potential investors and stakeholders tracking the progress of CNTB in the biopharmaceutical sector.

Biopharmaceuticals, Therapeutics, Dermatitis